Cargando…

Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized Controlled Trial

INTRODUCTION: Calciprotein particles (CPPs) are potentially modifiable mediators of phosphate toxicity in patients with kidney disease. We compared the effects of calcium carbonate (CC) and the non–calcium-based phosphate binder sevelamer on CPP levels in patients undergoing hemodialysis (HD). We hy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Edward R., Pan, Fei Fei M., Hewitson, Tim D., Toussaint, Nigel D., Holt, Stephen G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486191/ https://www.ncbi.nlm.nih.gov/pubmed/32954068 http://dx.doi.org/10.1016/j.ekir.2020.06.014

Ejemplares similares

Fetuin-A-Containing Calciprotein Particles Reduce Mineral Stress in the Macrophage
por: Smith, Edward R., et al.
Publicado: (2013)

Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells
por: Thiem, Ursula, et al.
Publicado: (2022)

The effect of lanthanum carbonate on calciprotein particles in hemodialysis patients
por: Nakamura, Kimihiko, et al.
Publicado: (2019)

Reduction of Calciprotein Particles in Adults Receiving Infliximab for Chronic Inflammatory Disease
por: Tiong, Mark K, et al.
Publicado: (2021)

Live Imaging of Calciprotein Particle Clearance and Receptor Mediated Uptake: Role of Calciprotein Monomers
por: Koeppert, Sina, et al.
Publicado: (2021)

Effects of fetuin-A-containing calciprotein particles on posttranslational modifications of fetuin-A in HepG2 cells
por: Uedono, Hideki, et al.
Publicado: (2021)

Reduced hip bone mineral density is associated with high levels of calciprotein particles in patients with Fabry disease
por: Bruell, S., et al.
Publicado: (2022)

Calciprotein Particles Cause Endothelial Dysfunction under Flow
por: Shishkova, Daria, et al.
Publicado: (2020)

Calciprotein Particles: Balancing Mineral Homeostasis and Vascular Pathology
por: Kutikhin, Anton G., et al.
Publicado: (2021)

Calciprotein Particle Synthesis Strategy Determines In Vitro Calcification Potential
por: Zeper, Lara W., et al.
Publicado: (2022)

Effect of nutritional calcium and phosphate loading on calciprotein particle kinetics in adults with normal and impaired kidney function
por: Tiong, Mark K., et al.
Publicado: (2022)

Klotho and calciprotein particles as therapeutic targets against accelerated ageing
por: Kuro-o, Makoto
Publicado: (2021)

Association between amorphous calcium-phosphate ratios in circulating calciprotein particles and prognostic biomarkers in hemodialysis patients
por: Nakamura, Kimihiko, et al.
Publicado: (2022)

Effect of lanthanum carbonate on serum calciprotein particles in patients with stage 3–4 CKD—results from a placebo-controlled randomized trial
por: Tiong, Mark K, et al.
Publicado: (2022)

Removal of calciprotein particles from the blood using an adsorption column improves prognosis of hemodialysis miniature pigs
por: Miura, Marina, et al.
Publicado: (2023)

Calciprotein particle inhibition explains magnesium-mediated protection against vascular calcification
por: ter Braake, Anique D, et al.
Publicado: (2019)

Cellular Clearance and Biological Activity of Calciprotein Particles Depend on Their Maturation State and Crystallinity
por: Köppert, Sina, et al.
Publicado: (2018)

Calciprotein Particles Induce Endothelial Dysfunction by Impairing Endothelial Nitric Oxide Metabolism
por: Feenstra, Lian, et al.
Publicado: (2023)

Biological and Clinical Effects of Calciprotein Particles on Chronic Kidney Disease-Mineral and Bone Disorder
por: Akiyama, Kenichi, et al.
Publicado: (2018)

Comparison of Sevelamer and Calcium Carbonate in Prevention of Hypomagnesemia in Hemodialysis Patients
por: Jandaghi, Elahe, et al.
Publicado: (2021)

Identification and quantification of plasma calciprotein particles with distinct physical properties in patients with chronic kidney disease
por: Miura, Yutaka, et al.
Publicado: (2018)

Calciprotein Particles and Serum Calcification Propensity: Hallmarks of Vascular Calcifications in Patients with Chronic Kidney Disease
por: Silaghi, Ciprian N., et al.
Publicado: (2020)

Calciprotein Particles Cause Physiologically Significant Pro-Inflammatory Response in Endothelial Cells and Systemic Circulation
por: Shishkova, Daria, et al.
Publicado: (2022)

Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients
por: Gonzalez, Elsa, et al.
Publicado: (2010)

Calcium-sensing receptor-mediated NLRP3 inflammasome response to calciprotein particles drives inflammation in rheumatoid arthritis
por: Jäger, Elisabeth, et al.
Publicado: (2020)

Calciprotein Particles Link Disturbed Mineral Homeostasis with Cardiovascular Disease by Causing Endothelial Dysfunction and Vascular Inflammation
por: Shishkova, Daria K., et al.
Publicado: (2021)

Calciprotein particles and fibroblast growth factor 23 contribute to the pathophysiology of hypercalcemia in a patient with renal sarcoidosis
por: Iwazu, Yoshitaka, et al.
Publicado: (2019)

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis
por: Savica, Vincenzo, et al.
Publicado: (2008)

Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients
por: Zeng, Qian, et al.
Publicado: (2023)

Ischemic Colitis in Association with Sevelamer Crystals
por: Keri, K. C., et al.
Publicado: (2019)

Gastrointestinal complications induced by sevelamer crystals
por: Yuste, Claudia, et al.
Publicado: (2017)

Sevelamer Carbonate Crystal-Induced Colitis
por: Lai, T., et al.
Publicado: (2020)

Calciprotein particle-induced cytotoxicity via lysosomal dysfunction and altered cholesterol distribution in renal epithelial HK-2 cells
por: Kunishige, Rina, et al.
Publicado: (2020)

Sevelamer-Induced Gastrointestinal Injury Presenting as Gastroenteritis
por: Magee, Jared, et al.
Publicado: (2018)

Sevelamer Attenuates Bioprosthetic Heart Valve Calcification
por: Meng, Zhen, et al.
Publicado: (2021)

Binding interactions with sevelamer and polystyrene sulfonate in vitro
por: van Berlo‐van de Laar, Inge R.F., et al.
Publicado: (2021)

A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis
por: Fan, Stanley, et al.
Publicado: (2009)

Development and Validation of a Gas Chromatography Method for the Trace Level Determination of Allylamine in Sevelamer Hydrochloride and Sevelamer Carbonate Drug Substances
por: Kadiyala, Raju V. S. N., et al.
Publicado: (2014)

Practical use of sevelamer in chronic kidney disease patients on dialysis in People’s Republic of China
por: Meng, Lin, et al.
Publicado: (2015)

Long-Term Effects of Sevelamer on Vascular Calcification, Arterial Stiffness, and Calcification Propensity in Patients Receiving Peritoneal Dialysis: The Randomized Pilot SERENE (Sevelamer on Vascular Calcification, Arterial Stiffness) Trial
por: Wang, Angela Yee-Moon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eotkdd1dcrgrdg4er4o0qkphi2